About the Authors
- José Manuel Molina-Guijarro
-
* E-mail: jmmolina@pharmamar.com
Affiliation Departamento de Investigación y Desarrollo, PharmaMar S.A., Colmenar Viejo, Madrid, Spain
- Carolina García
-
Affiliation Departamento de Química Física Biológica, Instituto de Química-Física “Rocasolano” (CSIC), Madrid, Spain
- Álvaro Macías
-
Affiliation Instituto de Investigaciones Biomédicas “Alberto Sols” (CSIC-UAM), Madrid, Spain
- Luis Francisco García-Fernández
-
Affiliation Departamento de Investigación y Desarrollo, PharmaMar S.A., Colmenar Viejo, Madrid, Spain
- Cristina Moreno
-
Current address: Department of Cardiology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Centre, Maastricht, The Netherlands
Affiliation Instituto de Investigaciones Biomédicas “Alberto Sols” (CSIC-UAM), Madrid, Spain
- Fernando Reyes
-
Affiliation Fundación MEDINA, Parque Tecnológico de Ciencias de la Salud, Armilla, Granada, Spain
- Juan Fernando Martínez-Leal
-
Affiliation Departamento de Investigación y Desarrollo, PharmaMar S.A., Colmenar Viejo, Madrid, Spain
- Rogelio Fernández
-
Affiliation Departamento de Investigación y Desarrollo, PharmaMar S.A., Colmenar Viejo, Madrid, Spain
- Valentín Martínez
-
Affiliation Departamento de Investigación y Desarrollo, PharmaMar S.A., Colmenar Viejo, Madrid, Spain
- Carmen Valenzuela
-
Affiliation Instituto de Investigaciones Biomédicas “Alberto Sols” (CSIC-UAM), Madrid, Spain
- M. Pilar Lillo
-
Affiliation Departamento de Química Física Biológica, Instituto de Química-Física “Rocasolano” (CSIC), Madrid, Spain
- Carlos M. Galmarini
-
Affiliation Departamento de Investigación y Desarrollo, PharmaMar S.A., Colmenar Viejo, Madrid, Spain
Competing Interests
The authors of this manuscript have read the journal's policy and have the following competing interests: José Manuel Molina-Guijarro, Luis Francisco García-Fernández, Juan Fernando Martínez-Leal, Rogelio Fernández, Valentín Martínez, and Carlos M. Galmarini are employees and shareholders of PharmaMar S.A. Actual patent application of elisidepsin belongs to PharmaMar SA. There are no products in development or marketed products to declare. This does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: JMMG LFGF FR CV MPL CMG. Performed the experiments: JMMG CG AM CM RF VM MPL. Analyzed the data: JMMG CG AM LFGF CM FR JFML RF VM CV MPL CMG. Contributed reagents/materials/analysis tools: JMMG CG AM LFGF CM FR JFML RF VM CV MPL CMG. Wrote the paper: JMMG CV MPL CMG.